EMA Recommendations To Minimize Risks With SGLT2 And Tysabri
This article was originally published in Scrip
The European Medicines Agency has confirmed the recommendations of its Pharmacovigilance Risk Assessment Committee (PRAC) to update the product information for the sodium-glucose co-transporter-2 (SGLT2) inhibitors, used to treat type 2 diabetes, to include diabetic ketoacidosis as a rare adverse reaction. The EMA has also recommended temporarily stopping SGLT2-inhibitor use in patients who are in hospital because of serious illness or are undergoing major surgery.
You may also be interested in...
A German case of PML in a patient treated with Ocrevus, but who was also previously treated with Tysabri, threatens to take the gloss off Roche’s new multiple sclerosis therapy.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.